Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

MLA

Xavier Quantin, et al. “Vemurafenib in Non-Small-Cell Lung Cancer Patients with BRAFV600 and BRAFnonV600 Mutations.” Annals of Oncology, vol. 31, Feb. 2020, pp. 289–94. EBSCOhost, https://doi.org/10.1016/j.annonc.2019.10.022.

APA

Xavier Quantin, Julien Mazieres, Samia Collot, P.J. Souquet, C. Tiffon, M. Jaffro, L. Favier, C. Mahier-Ait Oukhatar, Jacques Cadranel, Virginie Westeel, Jean Trédaniel, Claire Cropet, L. Montané, Fabrice Barlesi, Denis Moro-Sibilot, J. Le Treut, Etienne Brain, Gilbert Ferretti, J. Otto, … V. Avrillon. (2020). Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Annals of Oncology, 31, 289–294. https://doi.org/10.1016/j.annonc.2019.10.022

Chicago

Xavier Quantin, Julien Mazieres, Samia Collot, P.J. Souquet, C. Tiffon, M. Jaffro, L. Favier, et al. 2020. “Vemurafenib in Non-Small-Cell Lung Cancer Patients with BRAFV600 and BRAFnonV600 Mutations.” Annals of Oncology 31 (February): 289–94. doi:10.1016/j.annonc.2019.10.022.